| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 150, Issue 11 5104-5113, Copyright © 1993 by American Association of Immunologists
ARTICLES |
M Pemberton, G Anderson, V Vetvicka, DE Justus and GD Ross
Department of Surgery, University of Louisville, KY 40292.
Reperfusion of ischemic tissue is associated with tissue injury greater than that resulting from ischemia alone. C activation has been hypothesized to mediate the so-called ischemia/reperfusion injury through both membrane attack and C5a-dependent recruitment of neutrophils to sites of C3 fixation on the endothelium via C3 receptors. Adherence of neutrophils is preconditional to expression of their deleterious effects, which are central to the pathophysiology of ischemia/reperfusion injury. This study was designed to evaluate the effect of inhibition of C activation on ischemia/reperfusion injury using a soluble and truncated recombinant human CR1 (sCR1) molecule, a "tail-less" form of the membrane C3b/C4b receptor (CD35) that functions as a regulator of C activation. Capillary perfusion and leukocyte adherence to venular endothelium were measured after reperfusion in a mouse cremaster muscle model that allowed microscopic video observation of microcirculatory changes. Infusion i.v. with sCR1 before a 4-h period of ischemia and during a 3-h subsequent period of reperfusion prevented the increase in leukocyte adherence to venular endothelium seen in controls, and enhanced the number of reperfusing capillaries by 55%. Trypan blue staining showed an increase in muscle cell viability from 11 to 50% in mice receiving sCR1 as compared to controls. Tests of blood samples from mice infused with sCR1 demonstrated nearly complete inhibition of the mouse alternative pathway of C activation, but no detectable loss of the mouse classical pathway of C activation. It was concluded that C activation in this model of skeletal muscle injury is likely to be due to the alternative pathway, and that inhibition of C activation during reperfusion inhibits leukocyte adherence to blood vessel walls and protects the capillary microcirculation.
This article has been cited by other articles:
|
|
 |
|
  V. Ramaglia, R. Wolterman, M. de Kok, M. A. Vigar, I. Wagenaar-Bos, R. H. M. King, B. P. Morgan, and F. Baas Soluble Complement Receptor 1 Protects the Peripheral Nerve from Early Axon Loss after Injury Am. J. Pathol., April 1, 2008; 172(4): 1043 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Thurman, A. M. Lenderink, P. A. Royer, K. E. Coleman, J. Zhou, J. D. Lambris, R. A. Nemenoff, R. J. Quigg, and V. M. Holers C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion J. Immunol., February 1, 2007; 178(3): 1819 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Thurman, P. A. Royer, D. Ljubanovic, B. Dursun, A. M. Lenderink, C. L. Edelstein, and V. M. Holers Treatment with an Inhibitory Monoclonal Antibody to Mouse Factor B Protects Mice from Induction of Apoptosis and Renal Ischemia/Reperfusion Injury J. Am. Soc. Nephrol., March 1, 2006; 17(3): 707 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Walsh, T. Bourcier, K. Takahashi, L. Shi, M. N. Busche, R. P. Rother, S. D. Solomon, R. A. B. Ezekowitz, and G. L. Stahl Mannose-Binding Lectin Is a Regulator of Inflammation That Accompanies Myocardial Ischemia and Reperfusion Injury J. Immunol., July 1, 2005; 175(1): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Fleming, R. P. Egan, C. Chai, G. Girardi, V. M. Holers, J. Salmon, M. Monestier, and G. C. Tsokos Anti-Phospholipid Antibodies Restore Mesenteric Ischemia/Reperfusion-Induced Injury in Complement Receptor 2/Complement Receptor 1-Deficient Mice J. Immunol., December 1, 2004; 173(11): 7055 - 7061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Postma, M. J. Poppelier, J. C. van Galen, E. R. Prossnitz, J. A. G. van Strijp, C. J. C. de Haas, and K. P. M. van Kessel Chemotaxis Inhibitory Protein of Staphylococcus aureus Binds Specifically to the C5a and Formylated Peptide Receptor J. Immunol., June 1, 2004; 172(11): 6994 - 7001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. von Dobschuetz, O. Bleiziffer, S. Pahernik, M. Dellian, T. Hoffmann, and K. Messmer Soluble complement receptor 1 preserves endothelial barrier function and microcirculation in postischemic pancreatitis in the rat Am J Physiol Gastrointest Liver Physiol, May 1, 2004; 286(5): G791 - G796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J.C. de Haas, K. E. Veldkamp, A. Peschel, F. Weerkamp, W. J.B. Van Wamel, E. C.J.M. Heezius, M. J.J.G. Poppelier, K. P.M. Van Kessel, and J. A.G. van Strijp Chemotaxis Inhibitory Protein of Staphylococcus aureus, a Bacterial Antiinflammatory Agent J. Exp. Med., March 1, 2004; 199(5): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Merchant, D. M. Gurule, and R. S. Larson Amelioration of ischemia-reperfusion injury with cyclic peptide blockade of ICAM-1 Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1260 - H1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sumichika, K. Sakata, N. Sato, S. Takeshita, S. Ishibuchi, M. Nakamura, T. Kamahori, S. Ehara, K. Itoh, T. Ohtsuka, et al. Identification of a Potent and Orally Active Non-peptide C5a Receptor Antagonist J. Biol. Chem., December 13, 2002; 277(51): 49403 - 49407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. PARK, M. HAAS, P. N. CUNNINGHAM, J. J. ALEXANDER, L. BAO, J. M. GUTHRIDGE, D. M. KRAUS, V. M. HOLERS, and R. J. QUIGG Inhibiting the Complement System Does Not Reduce Injury in Renal Ischemia Reperfusion J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. KALLIO, K. B. LEMSTRÖM, P. J. HÄYRY, U. S. RYAN, and P. K. KOSKINEN Blockade of Complement Inhibits Obliterative Bronchiolitis in Rat Tracheal Allografts Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1332 - 1339. [Abstract] [Full Text]
|
|
|
|
|
|
Y. McGrath, G. W. G. Wilkinson, O. B. Spiller, and B. P. Morgan Development of Adenovirus Vectors Encoding Rat Complement Regulators for Use in Therapy in Rodent Models of Inflammatory Diseases J. Immunol., December 15, 1999; 163(12): 6834 - 6840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Tanhehco, K. Yasojima, P. L. McGeer, R. A. Washington, K. S. Kilgore, J. W. Homeister, and B. R. Lucchesi Preconditioning reduces tissue complement gene expression in the rabbit isolated heart Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2373 - H2380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huang, L. J. Kim, R. Mealey, H. C. Marsh Jr., Y. Zhang, A. J. Tenner, E. S. Connolly Jr., and D. J. Pinsky Neuronal Protection in Stroke by an sLex-Glycosylated Complement Inhibitory Protein Science, July 23, 1999; 285(5427): 595 - 599. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. P. Williams, T. T. V. Pechet, M. R. Weiser, R. Reid, L. Kobzik, F. D. Moore Jr., M. C. Carroll, and H. B. Hechtman Intestinal reperfusion injury is mediated by IgM and complement J Appl Physiol, March 1, 1999; 86(3): 938 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. O. Carter, C. Bull, E. Bortolon, L. Yang, G. J. Jesmok, and R. H. Gundel A murine skeletal muscle ischemia-reperfusion injury model: differential pathology in BALB/c and DBA/2N mice J Appl Physiol, November 1, 1998; 85(5): 1676 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Schmid, A. Zollinger, T. Singer, S. Hillinger, J. R. Leon-Wyss, O. M. Schob, K. Hogasen, G. Zund, G. A. Patterson, and W. Weder Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine J. Thorac. Cardiovasc. Surg., July 1, 1998; 116(1): 90 - 94. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Quigg, Y. Kozono, D. Berthiaume, A. Lim, D. J. Salant, A. Weinfeld, P. Griffin, E. Kremmer, and V. M. Holers Blockade of Antibody-Induced Glomerulonephritis with Crry-Ig, a Soluble Murine Complement Inhibitor J. Immunol., May 1, 1998; 160(9): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hammerberg, S. K. Katiyar, M. C. Carroll, and K. D. Cooper Activated Complement Component 3 (C3) Is Required for Ultraviolet Induction of Immunosuppression and Antigenic Tolerance J. Exp. Med., April 6, 1998; 187(7): 1133 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Henninger, M. E. Gerritsen, and D. N. Granger Low-Density Lipoprotein Receptor Knockout Mice Exhibit Exaggerated Microvascular Responses to Inflammatory Stimuli Circ. Res., August 19, 1997; 81(2): 274 - 281. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Moen, K. Hogasen, E. Fosse, E. Dregelid, V. Brockmeier, P. Venge, M. Harboe, and T. E. Mollnes Attenuation of Changes in Leukocyte Surface Markers and Complement Activation With Heparin-Coated Cardiopulmonary Bypass Ann. Thorac. Surg., January 1, 1997; 63(1): 105 - 111. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Park, M. Haas, P. N. Cunningham, L. Bao, J. J. Alexander, and R. J. Quigg Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes Am J Physiol Renal Physiol, February 1, 2002; 282(2): F352 - F357. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
